No significant differences were found between treatment and placebo groups on the ADAS-cog or CIBIC.

No significant difference between Tarenflurbil and placebo groups on the ADAS-cog or CIBIC.

No significant difference between Tramiprosate and placebo on the ADAS-cog or CIBIC.

No significant difference between Xaliprioden and placebo on the ADAS-cog or CIBIC.

No significant difference between Dimebon and placebo on the ADAS-cog, CIBIC-plus, or ADL.

The ability of the assessment instrument to show a treatment effect is a measure of the scale’s reliability. The inter-scale validity is not used for the assessment instrument is in the measurement of specific and secondary endpoint. All these phases show a critical role in assessing a high and low validity of the instrument.

The ability of the assessment instrument to show a treatment effect is a measure of the scale’s reliability. The inter-scale validity is not used for the assessment instrument is in the measurement of specific and secondary endpoint. All these phases show a critical role in assessing a high and low validity of the instrument.

Summary and Conclusions

- Commonly rating scales in AD trials have variability as determined by a number of factors. The variability in the clinical trials may contribute to negative AD efficacy trials and therefore has implications for planning future trials. Additional research is needed to better understand these implications for training and monitoring rating scales before and during the course of an AD trial.